XTL Biopharmaceuticals

About

Funding history · 10 rounds · $62.6M total

Headcount over time

Q&A

What is XTL Biopharmaceuticals' primary focus?

XTL Biopharmaceuticals is an Israeli biopharmaceutical company focused on the acquisition and development of pharmaceutical drugs for unmet clinical needs, with a recent strategic shift towards psychedelic medicine.

When did XTL Biopharmaceuticals go public on the London Stock Exchange?

XTL Biopharmaceuticals went public on the London Stock Exchange in September 2000, raising $44,000,000 with a valuation of $230,000,000.

When did XTL Biopharmaceuticals go public on NASDAQ?

XTL Biopharmaceuticals went public on NASDAQ in September 2005.

Who is the current CEO of XTL Biopharmaceuticals?

Mr. Noam Band was named the new Chief Executive Officer of XTL Biopharmaceuticals in April 2025.

What was a significant acquisition completed by XTL Biopharmaceuticals in 2026?

XTL Biopharmaceuticals completed the acquisition of Psyga Bio Ltd. in June 2026, establishing a psychedelic biotechnology platform.

What was the latest funding round for XTL Biopharmaceuticals?

XTL Biopharmaceuticals completed a PIPE funding round in June 2026, raising $1,500,000.

What is the current employee count for XTL Biopharmaceuticals?

XTL Biopharmaceuticals has 10 employees, which falls into the 1-10 employee bucket.

What was a recent acquisition by XTL Biopharmaceuticals in the autism market?

In January 2026, XTL Biopharmaceuticals acquired 85% of NeuroNOS, a subsidiary of Beyond Air, to enter the autism market.

Sectors & technology

Highlights

Tags